Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib followed by TPC in uHCC
NCT03433703Phase 2Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Eisai Co., Ltd.. Started Apr 2018; status: terminated.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03433703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03433703.